摘要
目的观察腺苷三磷酸结合盒转运体B1(ABCB1)基因C3435T多态性与激素冲击治疗急性视神经炎疗效的相关性。方法回顾性收集244例(322眼)急性视神经炎患者的临床资料,以激素冲击治疗后中心视力改变作为评价指标,分为激素敏感组和激素抵抗组。分析比较组间临床指标差异及C3435T各基因型组激素抵抗发生率,最后以Logistic回归筛选出可能造成激素抵抗的危险因素。结果患者年龄、初始视功能、视神经炎类型以及激素冲击治疗开始时间组间差异有统计学意义,是可能影响激素疗效的重要因素(均P <0. 05); ABCB1C3435T的CC、CT与TT型的GR发生率分别为42. 1%,35. 1%,21. 3%,组间差异有统计学意义(P <0. 05); Logistic回归分析结果提示年龄、视神经炎类型、初始视野以及ABCB1 C3435T分型为激素抵抗的危险因素(均P <0. 05)。结论 ABCB1基因C3435T多态性与激素治疗急性视神经炎的疗效具有相关性。
Objective To investigate the relationship between the ATP binding cassette transporter B1(ABCB1)gene C3435 T polymorphism and the therapeutic effect of glucocorticoid shock therapy on acute optic neuritis.Methods Clinical data of 244 patients(322 eyes)with acute optic neuritis were retrospectively collected.The patients were divided into glucocorticoid sensitive(GS)group or glucocorticoid resistance(GR)group according to the changes of central visual acuity after therapy.We analyzed and compared the differences of clinical indexes between groups,and incidence of GR in C3435 T genotypes.Finally,Logistic regression was used to screen out the risk factors of GR.Results Age,the initial visual function,the type of optic neuritis and the onset time of glucocorticoid therapy were significant factors that might affect the effect of hormone therapy(all P<0.05).The incidence of GR in CC,CT and TT type was 42.1%,35.1%and 21.3%,respectively,and the difference was statistically significant(P<0.05).Logistic regression analysis showed that age,type of optic neuritis,initial visual field and ABCB1 C3435 T were risk factors of GR(all P<0.05).Conclusion The polymorphism of ABCB1 gene C3435 T is associated with the therapeutic effect of glucocorticoid shock therapy on acute optic neuritis.
作者
戴玉洋
李嘉静
倪四阳
武峰
郭韶洁
王淑民
韩颖
赵秀丽
DAI Yu-yang;LI Jia-jing;NI Si-yang;WU Feng;GUO Shao-jie;WANG Shu-min;HAN Ying;ZHAO Xiu-li(National Institute for Drug Clinical Trial,Beijing Tongren Hospital,Capital Medical University,Beijng 100730,China;College of Pharmacy,Capital Medical University,Beijing 100069,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2019年第10期957-959,共3页
The Chinese Journal of Clinical Pharmacology
基金
国家"十二.五"重大新药创新科技重大专项基金资助项目(2011ZX09302-007-05)
